Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Toon andere (1) versies

Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Kari Hemminki, Asta Försti, Akseli Hemminki, Börje Ljungberg, Otto Hemminki
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Public Library of Science (PLoS) 2022-01-01
Reeks:	PLoS ONE
Online toegang:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0261124&type=printable

Gelijkaardige items

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
door: Kari Hemminki, et al.
Gepubliceerd in: (2022-01-01)

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
door: Kari Hemminki, et al.
Gepubliceerd in: (2021-01-01)

Survival in colon and rectal cancers in Finland and Sweden through 50 years
door: Akseli Hemminki, et al.
Gepubliceerd in: (2021-10-01)

Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor
door: Kari Hemminki, et al.
Gepubliceerd in: (2021-05-01)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
door: Kari Hemminki, et al.
Gepubliceerd in: (2022-04-01)

Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century.
door: Anni Koskinen, et al.
Gepubliceerd in: (2022-01-01)

Bladder and upper urinary tract cancers as first and second primary cancers
door: Guoqiao Zheng, et al.
Gepubliceerd in: (2021-12-01)

Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis
door: Kari Hemminki, et al.
Gepubliceerd in: (2024-04-01)

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries
door: Filip Tichanek, et al.
Gepubliceerd in: (2023-01-01)

Survival in gastric and esophageal cancers in the Nordic countries through a half century
door: Kari Hemminki, et al.
Gepubliceerd in: (2023-05-01)

Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries
door: Kari Hemminki, et al.
Gepubliceerd in: (2022-12-01)

Conditional survival in breast cancer up to 10 years in the Nordic countries
door: Frantisek Zitricky, et al.
Gepubliceerd in: (2023-09-01)

Survival trends in hematological malignancies in the Nordic countries through 50 years
door: Kari Hemminki, et al.
Gepubliceerd in: (2022-11-01)

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients
door: Kari Hemminki, et al.
Gepubliceerd in: (2024-08-01)

High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers
door: Kari Hemminki, et al.
Gepubliceerd in: (2025-02-01)

Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century
door: Frantisek Zitricky, et al.
Gepubliceerd in: (2024-01-01)

Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers
door: Kari Hemminki, et al.
Gepubliceerd in: (2025-02-01)

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
door: Kari Hemminki, et al.
Gepubliceerd in: (2021-08-01)

Incidence and survival in non-hereditary amyloidosis in Sweden
door: Hemminki Kari, et al.
Gepubliceerd in: (2012-11-01)

Familial risks in and between stone diseases: sialolithiasis, urolithiasis and cholelithiasis in the population of Sweden
door: Kari Hemminki, et al.
Gepubliceerd in: (2018-07-01)

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
door: Guoqiao Zheng, et al.
Gepubliceerd in: (2020-11-01)

Epidemiology of Amyloidosis and Genetic Pathways to Diagnosis and Typing
door: Kari Hemminki, et al.
Gepubliceerd in: (2021-07-01)

Family history of any cancer for childhood leukemia patients in Sweden
door: Xinjun Li, et al.
Gepubliceerd in: (2021-08-01)

Survival in Thyroid Cancer in Sweden From 1999 To 2018
door: Zitricky F, et al.
Gepubliceerd in: (2024-10-01)

Second cancers and causes of death in patients with testicular cancer in Sweden.
door: Luyao Zhang, et al.
Gepubliceerd in: (2019-01-01)

Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer
door: Riihimäki Matias, et al.
Gepubliceerd in: (2013-01-01)

Prostate cancer survivors: Risk and mortality in second primary cancers
door: Subhayan Chattopadhyay, et al.
Gepubliceerd in: (2018-11-01)

Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis
door: Kari Hemminki, et al.
Gepubliceerd in: (2017-08-01)

Survival in Lung Cancer in the Nordic Countries Through A Half Century
door: Tichanek F, et al.
Gepubliceerd in: (2023-05-01)

Survival in common cancers defined by risk and survival of family members
door: Jianguang Ji, et al.
Gepubliceerd in: (2011-10-01)

Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden
door: Hauke Thomsen, et al.
Gepubliceerd in: (2020-01-01)

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
door: Guoqiao Zheng, et al.
Gepubliceerd in: (2021-02-01)

Familial Associations of Colorectal Cancer with Other Cancers
door: Hongyao Yu, et al.
Gepubliceerd in: (2017-07-01)

Oncolytic viruses for cancer immunotherapy
door: Otto Hemminki, et al.
Gepubliceerd in: (2020-06-01)

The 'common disease-common variant' hypothesis and familial risks.
door: Kari Hemminki, et al.
Gepubliceerd in: (2008-01-01)

Oncolytic Immunotherapy: Where Are We Clinically?
door: Akseli Hemminki
Gepubliceerd in: (2014-01-01)

Portrait of a Leader in Immunotherapeutics<subtitle>Oncolytic viruses for treatment of cancer</subtitle>
door: Akseli Hemminki
Gepubliceerd in: (2012-08-01)

TILT Biotherapeutics
door: Akseli Hemminki
Gepubliceerd in: (2017-05-01)

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
door: Otto Hemminki, et al.
Gepubliceerd in: (2020-12-01)

Are population level familial risks and germline genetics meeting each other?
door: Kari Hemminki, et al.
Gepubliceerd in: (2023-03-01)